Tags: fatty liver disease | obeticholic acid | on-alcoholic steatohepatitis | liver inflammation

Drug for Fatty Liver Works in Trial

Thursday, 09 Jan 2014 12:16 PM


Intercept Pharmaceuticals Inc said an analysis by an independent safety committee showed that its liver disease drug met the main goal of a mid-stage trial, sending the company's shares soaring.
Intercept shares more than doubled to $169 in premarket trading on Thursday.
The company said it had stopped the trial after the committee found that the drug, obeticholic acid, showed statistically significant improvement in patients, compared with a placebo.
Nasdaq-listed Intercept said the committee made the recommendation after reviewing liver biopsy data from about half of the 283 patients enrolled in the trial.
The trial tested the drug in patients with non-alcoholic steatohepatitis, a form of liver inflammation caused by a build-up of fat.

© 2015 Thomson/Reuters. All rights reserved.

Around the Web
Please review Community Guidelines before posting a comment.
>> Register to share your comments with the community.
>> Login if you are already a member.
blog comments powered by Disqus
Zip Code:
Privacy: We never share your email.
Find Your Condition
You May Also Like
Around the Web
Most Commented

The information presented on this website is not intended as specific medical advice and is not a substitute for professional medical treatment or diagnosis. Read Newsmax Terms and Conditions of Service.

Newsmax, Moneynews, Newsmax Health, and Independent. American. are registered trademarks of Newsmax Media, Inc. Newsmax TV, and Newsmax World are trademarks of Newsmax Media, Inc.

© Newsmax Media, Inc.
All Rights Reserved
> >